Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BSEM BioStem Technologies	$13.65 -0.7%	$12.68	$6.77 ▼ $28.26	$228.01M	-0.32	66,578 shs	15,693 shs
LENZ LENZ Therapeutics	$28.82 -0.6%	$27.15	$16.28 ▼ $38.93	$811.17M	0.42	190,857 shs	186,647 shs
PHAR Pharming Group	$11.30 +5.1%	$9.70	$6.65 ▼ $12.61	$768.55M	0.02	6,233 shs	5,054 shs
STAA STAAR Surgical	$16.99 -0.5%	$17.87	$13.50 ▼ $49.86	$841.45M	0.63	851,853 shs	620,015 shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BSEM BioStem Technologies	-0.73%	-4.57%	+10.17%	+42.48%	+85.71%
LENZ LENZ Therapeutics	-0.62%	-7.69%	+7.50%	+18.11%	+55.45%
PHAR Pharming Group	+3.92%	-4.34%	+19.79%	+28.38%	+31.36%
STAA STAAR Surgical	-0.53%	-1.05%	-11.60%	-7.06%	-58.78%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BSEM BioStem Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	1.5073 of 5 stars	3.6	1.0	0.0	0.0	2.2	0.8	0.0
PHAR Pharming Group	2.1988 of 5 stars	3.5	3.0	0.0	0.0	2.6	0.0	0.6
STAA STAAR Surgical	3.9434 of 5 stars	3.0	2.0	0.0	4.1	1.9	3.3	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BSEM BioStem Technologies	0.00	N/A	N/A	N/A
LENZ LENZ Therapeutics	3.17	Buy	$46.60	61.69% Upside
PHAR Pharming Group	3.00	Buy	$30.00	165.56% Upside
STAA STAAR Surgical	2.00	Hold	$24.63	44.94% Upside

Current Analyst Ratings Breakdown

Latest BSEM, PHAR, STAA, and LENZ Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/27/2025	STAA STAAR Surgical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold	$20.00
5/21/2025	STAA STAAR Surgical	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/8/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
5/8/2025	STAA STAAR Surgical	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$17.00 ➝ $20.00
4/21/2025	STAA STAAR Surgical	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Equal Weight	$17.00
4/16/2025	LENZ LENZ Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$38.00 ➝ $38.00
4/14/2025	LENZ LENZ Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight ➝ Overweight	$38.00 ➝ $51.00
3/20/2025	LENZ LENZ Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$44.00 ➝ $47.00
3/20/2025	PHAR Pharming Group	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$37.00 ➝ $37.00
3/18/2025	LENZ LENZ Therapeutics	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$60.00
3/18/2025	STAA STAAR Surgical	Stephens Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Equal Weight ➝ Equal Weight	$17.00 ➝ $17.00

(Data available from 6/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BSEM BioStem Technologies	$16.68M	13.67	N/A	N/A	N/A	∞
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	$22.06 per share	N/A
PHAR Pharming Group	$320.71M	2.40	$0.12 per share	91.82	$3.26 per share	3.47
STAA STAAR Surgical	$279.13M	3.01	$0.74 per share	23.02	$7.91 per share	2.15

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BSEM BioStem Technologies	N/A	$1.47	20.07	5.96	N/A	N/A	N/A	N/A	8/11/2025 (Estimated)
LENZ LENZ Therapeutics	-$124.65M	-$1.77	N/A	N/A	N/A	N/A	-58.48%	-55.50%	8/13/2025 (Estimated)
PHAR Pharming Group	-$10.55M	-$0.20	N/A	376.57	N/A	-6.09%	-7.65%	-3.82%	7/30/2025 (Estimated)
STAA STAAR Surgical	-$20.21M	-$1.44	N/A	N/A	N/A	-6.44%	-3.35%	-2.67%	8/6/2025 (Estimated)

Latest BSEM, PHAR, STAA, and LENZ Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q4 2024	BSEM BioStem Technologies	$1.25	$0.17	-$1.08	$0.17	$101.20 million	$72.53 million
5/8/2025	Q1 2025	PHAR Pharming Group	-$0.25	-$0.22	+$0.03	-$0.22	$67.74 million	$79.09 million
5/7/2025	Q1 2025	LENZ LENZ Therapeutics	-$0.55	-$0.53	+$0.02	-$0.53	N/A	N/A
3/19/2025	Q4 2024	LENZ LENZ Therapeutics	-$0.42	-$0.46	-$0.04	-$0.46	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BSEM BioStem Technologies	N/A	N/A	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	N/A	N/A	N/A	N/A
PHAR Pharming Group	N/A	N/A	N/A	N/A	N/A
STAA STAAR Surgical	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BSEM BioStem Technologies	N/A	N/A	N/A
LENZ LENZ Therapeutics	N/A	28.63	28.63
PHAR Pharming Group	0.41	3.53	2.76
STAA STAAR Surgical	N/A	5.99	5.38

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BSEM BioStem Technologies	N/A
LENZ LENZ Therapeutics	54.32%
PHAR Pharming Group	0.03%
STAA STAAR Surgical	96.70%

Insider Ownership

Company	Insider Ownership
BSEM BioStem Technologies	N/A
LENZ LENZ Therapeutics	6.90%
PHAR Pharming Group	2.07%
STAA STAAR Surgical	1.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BSEM BioStem Technologies	N/A	16.70 million	N/A	N/A
LENZ LENZ Therapeutics	110	28.15 million	16.94 million	N/A
PHAR Pharming Group	280	68.03 million	66.62 million	Not Optionable
STAA STAAR Surgical	960	49.53 million	48.78 million	Optionable

BSEM, PHAR, STAA, and LENZ Headlines

Recent News About These Companies

STAA Q1 Earnings Call: Tariff Mitigation, Cost Cuts, and China Inventory Reshape Outlook

June 11, 2025 | finance.yahoo.com

STAAR Surgical (NASDAQ:STAA) Stock Price Down 3.1% - Here's Why

June 11, 2025 | marketbeat.com

STAAR Surgical (NASDAQ:STAA) Receives $24.63 Consensus PT from Analysts

June 8, 2025 | americanbankingnews.com

BLOG: What I’ve learned (and like) about office-based surgery

June 6, 2025 | healio.com

STAAR Surgical (NASDAQ:STAA) Trading 5.3% Higher - Still a Buy?

June 5, 2025 | marketbeat.com

Cautious Optimism for Staar Surgical Amidst Uncertain Macroeconomic Recovery and Market Shifts

June 5, 2025 | tipranks.com

STAAR Surgical (NASDAQ:STAA) Given Average Recommendation of "Hold" by Analysts

June 5, 2025 | marketbeat.com

STAAR Surgical at William Blair Conference: Strategic Shifts Amid Challenges

June 4, 2025 | investing.com

Jane Street Group LLC Sells 71,466 Shares of STAAR Surgical (NASDAQ:STAA)

June 4, 2025 | marketbeat.com

STAAR Surgical (NASDAQ:STAA) Shares Down 4.7% - Time to Sell?

May 29, 2025 | marketbeat.com

Squarepoint Ops LLC Increases Stock Holdings in STAAR Surgical (NASDAQ:STAA)

May 29, 2025 | marketbeat.com

Why LASIK Isn’t for Everyone: Houston Lasik & Eye Introduces EVO ICL as a Personalized Solution

May 28, 2025 | usatoday.com

Office-based surgery offers satisfaction for patients, ‘rebirth’ for surgeons

May 28, 2025 | healio.com

STAAR Surgical (NASDAQ:STAA) Earns "Hold" Rating from Canaccord Genuity Group

May 28, 2025 | marketbeat.com

1 Cash-Heavy Stock Worth Your Attention and 2 to Steer Clear Of

May 27, 2025 | finance.yahoo.com

STAAR Surgical at Stifel Forum: Strategic Moves and Market Challenges

May 27, 2025 | investing.com

Voloridge Investment Management LLC Grows Stock Holdings in STAAR Surgical (NASDAQ:STAA)

May 27, 2025 | marketbeat.com

Ameriprise Financial Inc. Raises Position in STAAR Surgical (NASDAQ:STAA)

May 27, 2025 | marketbeat.com

Staar Surgical Q1 Sales Drop 45% on Weak China Demand

May 26, 2025 | ocbj.com

STAAR Surgical (NASDAQ:STAA) Shares Sold by Bank of America Corp DE

May 26, 2025 | marketbeat.com

Millennium Management LLC Sells 173,179 Shares of STAAR Surgical (NASDAQ:STAA)

May 24, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Defense Stocks That Will Profit From a Golden Dome
By Chris Markoch | May 30, 2025
View 3 Defense Stocks That Will Profit From a Golden Dome
Analysts Think These Stocks Could More Than Double in Value
By Nathan Reiff | May 23, 2025
View Analysts Think These Stocks Could More Than Double in Value
These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio
By Leo Miller | May 22, 2025
View These Are the Only 6 Stock Stocks in NVIDIA's 13F Portfolio
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
By Nathan Reiff | June 12, 2025
View Analysts Can't Get Enough of These Little-Known Biopharma Stocks
Eli Lilly : A Breakout Biotech Powerhouse With Room to Run
By Jeffrey Neal Johnson | May 29, 2025
View Eli Lilly : A Breakout Biotech Powerhouse With Room to Run

BSEM, PHAR, STAA, and LENZ Company Descriptions

BioStem Technologies OTCMKTS:BSEM

$13.65 -0.10 (-0.73%)

As of 06/16/2025 03:57 PM Eastern

BioStem Technologies, Inc., a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases. The company is also engages in the repackaging and distribution of active pharmaceutical ingredients and other pharmaceutical compounding supplies; and develops and markets nutraceutical products under the Dr. Dave's Best and Nesvik Organics brands, as well as other non-proprietary products in the United States and internationally. The company sells products through e-commerce platforms. BioStem Technologies, Inc. was incorporated in 2006 and is based in Pompano Beach, Florida.

LENZ Therapeutics NASDAQ:LENZ

$28.82 -0.18 (-0.62%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$28.79 -0.03 (-0.12%)

As of 06/16/2025 07:54 PM Eastern

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

Pharming Group NASDAQ:PHAR

$11.30 +0.55 (+5.09%)

Closing price 06/16/2025 03:59 PM Eastern

Extended Trading

$11.15 -0.15 (-1.29%)

As of 06/16/2025 06:58 PM Eastern

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.

STAAR Surgical NASDAQ:STAA

$16.99 -0.09 (-0.53%)

Closing price 06/16/2025 04:00 PM Eastern

Extended Trading

$17.00 +0.02 (+0.09%)

As of 06/16/2025 04:20 PM Eastern

STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time